CRISPR-Cas modified cell therapies for cancer
| National Clinical Trial identifier . | Clinical trial phase . | Cancer type . | CRISPR target . | Cell source . | Method of CRISPR . | Other cell engineering . | Status . | Location . |
|---|---|---|---|---|---|---|---|---|
| NCT04037566 | 1 | Relapsed or refractory ALL and B-cell lymphoma | HPK1 | Autologous T cells | Electroporation of RNP | CD19 CAR lentiviral vector | Recruiting | China |
| NCT03399448 | 1 | Multiple myeloma | Endogenous TCRα, TCRβ, and PD-1 | Autologous T cells | Electroporation of RNP | NYESO-1 TCR lentiviral vector | Active, not recruiting | University of Pennsylvania |
| Melanoma | ||||||||
| Synovial sarcoma | ||||||||
| Myxoid/round cell liposarcoma | ||||||||
| NCT03164135 | 1 | Hematologic malignancies with HIV infection | CCR5 | CD34+ hematopoietic stem/progenitor cells | Unknown | None | Recruiting | China |
| NCT03545815 | 1 | Mesothelin positive | Endogenous TCR and PD-1 | T cells, unknown source | Unknown | Anti-mesothelin CAR | Recruiting | China |
| Solid tumors | ||||||||
| NCT04244656 | 1 | Refractory multiple myeloma | TCR and β2 M gene | Allogeneic T cells | Unknown | Anti-BCMA CAR insertion at the TRAC locus | Recruiting | USA (Nashville and Oregon) and Australia |
| NCT03747965 | 1 | Mesothelin positive | PD-1 | T cells, unknown source | Unknown | Anti-mesothelin CAR | Recruiting | China |
| Solid tumors | ||||||||
| NCT04035434 | 1/2 | B-cell malignancies | TCR and β2 M gene | Allogeneic T cells | Unknown | Anti-CD19 CAR insertion at the TRAC locus | Recruiting | Multiple sites in USA and Australia |
| NCT03166878 | 1/2 | B-cell leukemia and lymphoma | TCR and β2 M gene | Allogeneic T cells from healthy unrelated donors | Electroporation of RNP | Anti-CD19 CAR, lentiviral vector 41BB-CD3ζ | Recruiting | China |
| NCT03044743 | 1/2 | EBV associated malignancies | PD-1 | EBV CTL from autologous source | Unknown | None | Recruiting | China |
| National Clinical Trial identifier . | Clinical trial phase . | Cancer type . | CRISPR target . | Cell source . | Method of CRISPR . | Other cell engineering . | Status . | Location . |
|---|---|---|---|---|---|---|---|---|
| NCT04037566 | 1 | Relapsed or refractory ALL and B-cell lymphoma | HPK1 | Autologous T cells | Electroporation of RNP | CD19 CAR lentiviral vector | Recruiting | China |
| NCT03399448 | 1 | Multiple myeloma | Endogenous TCRα, TCRβ, and PD-1 | Autologous T cells | Electroporation of RNP | NYESO-1 TCR lentiviral vector | Active, not recruiting | University of Pennsylvania |
| Melanoma | ||||||||
| Synovial sarcoma | ||||||||
| Myxoid/round cell liposarcoma | ||||||||
| NCT03164135 | 1 | Hematologic malignancies with HIV infection | CCR5 | CD34+ hematopoietic stem/progenitor cells | Unknown | None | Recruiting | China |
| NCT03545815 | 1 | Mesothelin positive | Endogenous TCR and PD-1 | T cells, unknown source | Unknown | Anti-mesothelin CAR | Recruiting | China |
| Solid tumors | ||||||||
| NCT04244656 | 1 | Refractory multiple myeloma | TCR and β2 M gene | Allogeneic T cells | Unknown | Anti-BCMA CAR insertion at the TRAC locus | Recruiting | USA (Nashville and Oregon) and Australia |
| NCT03747965 | 1 | Mesothelin positive | PD-1 | T cells, unknown source | Unknown | Anti-mesothelin CAR | Recruiting | China |
| Solid tumors | ||||||||
| NCT04035434 | 1/2 | B-cell malignancies | TCR and β2 M gene | Allogeneic T cells | Unknown | Anti-CD19 CAR insertion at the TRAC locus | Recruiting | Multiple sites in USA and Australia |
| NCT03166878 | 1/2 | B-cell leukemia and lymphoma | TCR and β2 M gene | Allogeneic T cells from healthy unrelated donors | Electroporation of RNP | Anti-CD19 CAR, lentiviral vector 41BB-CD3ζ | Recruiting | China |
| NCT03044743 | 1/2 | EBV associated malignancies | PD-1 | EBV CTL from autologous source | Unknown | None | Recruiting | China |
BCMA, B-cell maturation antigen; EBV, Epstein–Barr virus; HPK1, hematopoietic progenitor kinase 1; NYESO-1, New York esophageal squamous cell carcinoma 1; RNP, ribonucleoprotein; TRAC, T-cell receptor-α constant.